Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5049 - liver surgery of breast cancer liver metastases: rapid surgical decision after diagnosis does not negatively impact long-term results

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Surgical Oncology

Tumour Site

Breast Cancer

Presenters

Valerio Lucidi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

V. Lucidi1, G. Liberale2, D. Germanova3, M. Bez4, V. Donckier5

Author affiliations

  • 1 Digestive Surgery, Hepatobiliary Surgery & Liver Transplantation, erasme University Hospital-(Universite Libre de Bruxelles), 1070 - Brussels/BE
  • 2 Surgery, Institut Jules Bordet, 10001 - Brussels/BE
  • 3 Digestive Surgery, Erasme University Hospital ULB, 1070 - Brussels/BE
  • 4 Digestive Surgery, Hepatobiliary Surgery & Liver Transplantation, Erasme University Hospital-(Universite Libre de Bruxelles), 1070 - Brussels/BE
  • 5 Surgery, Institute Jules Bordet, 1000 - Brussels/BE
More

Resources

Abstract 5049

Background

Surgery could be indicated in selected patients with breast cancer liver metastases (BCLM) but accurate identification of the candidates for surgery remains a challenge. We investigated if an observational period of time after the diagnosis of BCLM could improve the selection for surgery.

Methods

We performed a retrospective analysis of 72 consecutive patients operated for BCLM between 2000 and 2015. Clinicopathologic and outcome data were compared between 2 groups: Early surgery (ES), including patients operated for BCLM ≤12 months after liver metastases (LM) diagnosis, and late surgery (LS), including patients operated >12 months after diagnosis.

Results

Mean age was 48 years (28-74) at time of liver surgery. Median time between primary and LM diagnosis was 35 months (0-211) and median time between LM diagnosis and surgery was 12 months (0-134). Clinicopathologic characteristics were similar in ES (n = 37) and LS (n = 35) patients. In the whole population, 1, 3 and 5-years progression free (PFS) and overall (OS) survivals were respectively of 70%, 43%, 30% and 93%, 66%, 43%. In multivariate analysis, neither PFS nor OS differences were observed between ES and LS groups (PFS - HR = 1,13 p = 0,72 and OS - HR = 1,06, p = 0,85 for LS), only primary tumor estrogen receptor positivity had a positive impact for OS (HR = 0,48 p = 0,05).

Conclusions

No difference in survival was observed between patients operated rapidly for BCLM as compared with patients operated after observational period, suggesting that it is not necessary to postpone the surgery in patients with resectable LM.

Clinical trial identification

Legal entity responsible for the study

Hôpital Erasme ULB.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.